We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Report shows 300% increase in demand for GLP-1 weight loss and diabetes drugs
New rules are designed to make medicines cheaper for American seniors. But companies warn innovation will suffer
Medicare’s negotiations on the cost of medicines could affect how drug research is funded globally
Efforts to rein in soaring health costs have already hit corporate shares but the sell-off looks premature
Expensive medicines made by Pfizer, J&J and Merck selected for talks in biggest shake-up in decades
Anglo-Swedish group is latest to challenge Medicare’s new power to negotiate prices for a limited number of medicines
Companies say system will dent market competition for new off-patent medicines in coming years
A new study bolsters the case that semaglutide is not merely a vanity drug but has a key role to play in treating obesity
Legal and regulatory actions are more likely to drag on earnings than negate them
Pharma industry deprioritising certain pills with shorter exclusivity period, says head of Swiss drugmaker
A decade ago a large part of Big Pharma gave up on one of humanity’s cruellest diseases. But then a new treatment showed promise
Successful pilot in England will be expanded to more pharma companies and include N Ireland, Scotland and Wales
Pharmaceutical group says parts of law are unconstitutional
UK unveils reforms worth £650mn to boost the life sciences sector
Manufacturers racing to build what could be one of industry’s biggest markets must tread with care
If ban becomes permanent, challenges to FDA’s authority by special interest groups could proliferate
Chief executive says draft plan to cut market exclusivity protection could make pursuing some treatments unviable
Swiss group rethinks NHS collaboration after low take-up of treatment during rollout via GPs
Pharma group’s decision comes in response to US political pressure over high cost of diabetes medication
Health department says industry’s plan, published ahead of talks, would limit access to new medicines
UK pharma industry claims that de facto tax will hurt research and development investment
Specialist drugs sold by Big Pharma are so expensive that many patients are being excluded
Drugmaker taken to court by public interest group for abusing market position and profiteering
Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch
Tight budgets and US reforms are ending a truce between the industry and health authorities
UK Edition
